BIOMAT Database Logo BIOMAT Database Logo

Activation of the alternative pathway of complement by mycobacteria and cord factor. 1980

V D Ramanathan, and J Curtis, and J L Turk

The ability of a number of mycobacteria and some of their components to activate complement was examined. Mycobacterium bovis BCG (Glaxo strain), Mycobacterium leprae, Mycobacterium lepraemurium, and cord factor activated the alternative pathway of complement in normal human serum and normal and C4-deficient guinea pig sera and generated biologically active products. BCG (Pasteur strain) and muramyl dipeptide did not activate complement. The relevance of activation of complement by mycobacteria to their induction of granulomas is discussed.

UI MeSH Term Description Entries
D009163 Mycobacterium bovis The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis. BCG,Calmette-Guerin Bacillus
D009166 Mycobacterium leprae A species of gram-positive, aerobic bacteria that causes LEPROSY in man. Its organisms are generally arranged in clumps, rounded masses, or in groups of bacilli side by side.
D009167 Mycobacterium lepraemurium The etiologic agent of rat leprosy, also known as murine leprosy.
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003170 Complement Pathway, Alternative Complement activation initiated by the interaction of microbial ANTIGENS with COMPLEMENT C3B. When COMPLEMENT FACTOR B binds to the membrane-bound C3b, COMPLEMENT FACTOR D cleaves it to form alternative C3 CONVERTASE (C3BBB) which, stabilized by COMPLEMENT FACTOR P, is able to cleave multiple COMPLEMENT C3 to form alternative C5 CONVERTASE (C3BBB3B) leading to cleavage of COMPLEMENT C5 and the assembly of COMPLEMENT MEMBRANE ATTACK COMPLEX. Alternative Complement Pathway,Properdin Pathway,Alternative Complement Activation Pathway,Complement Activation Pathway, Alternative
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D003311 Cord Factors Toxic glycolipids composed of trehalose dimycolate derivatives. They are produced by MYCOBACTERIUM TUBERCULOSIS and other species of MYCOBACTERIUM. They induce cellular dysfunction in animals. Trehalose Dimycolates,Cord Factor,Trehalose-6,6'-Dimycolate,Dimycolates, Trehalose,Factor, Cord,Factors, Cord,Trehalose 6,6' Dimycolate
D006017 Glycolipids Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage) Glycolipid
D006020 Glycopeptides Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. Glycopeptide
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea

Related Publications

V D Ramanathan, and J Curtis, and J L Turk
Plasma factor triggering alternative complement pathway activation by liposomes.
March 1994, Pharmaceutical research,
V D Ramanathan, and J Curtis, and J L Turk
Inhibiting alternative pathway complement activation by targeting the factor D exosite.
April 2012, The Journal of biological chemistry,
V D Ramanathan, and J Curtis, and J L Turk
Activation of the alternative pathway of complement by antiserum to factor B.
March 1979, The Journal of laboratory and clinical medicine,
V D Ramanathan, and J Curtis, and J L Turk
Complement factor B and the alternative pathway of complement activation in bovine milk.
February 2002, The Journal of dairy research,
V D Ramanathan, and J Curtis, and J L Turk
Activation of human complement by liposomes: serum factor requirement for alternative pathway activation.
August 1980, Journal of immunology (Baltimore, Md. : 1950),
V D Ramanathan, and J Curtis, and J L Turk
Activation of the alternative complement pathway and production of factor H by skeletal myotubes.
May 1993, Journal of neuroimmunology,
V D Ramanathan, and J Curtis, and J L Turk
The alternative pathway of complement activation.
January 1976, Advances in immunology,
V D Ramanathan, and J Curtis, and J L Turk
Activation of the alternative complement pathway.
November 1979, CRC Critical reviews in immunology,
V D Ramanathan, and J Curtis, and J L Turk
Classical and alternative complement pathway activation by pneumococci.
August 1977, Infection and immunity,
V D Ramanathan, and J Curtis, and J L Turk
Alternative complement pathway activation by C4b deposited during classical pathway activation.
April 1986, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!